Introduction/Overview
Valeriana officinalis L., as a traditional medicinal plant, has a long history of calming and calming the nerves in both Eastern and Western medical systems. Modern pharmacological research has revealed that a class of characteristic components rich in the roots and stems of Valeriana officinalis, namely Valepotriates, are the main active groups that exert central nervous system regulatory effects. Among them, Valtrate, as one of the most abundant and extensively studied characteristic compounds in this family, has become a research hotspot in the field of natural product pharmacology since its structure was elucidated. Valerian is a unique fatty acid ester compound, and its complex cyclic ether terpene ester structure endows it with diverse biological activities, especially showing significant potential in sedation, hypnosis, anti anxiety, and other areas. With the increase of the incidence rate of mental stress related diseases in modern society, the demand for new sedative hypnotics with high efficiency and low toxicity is increasingly urgent, which makes the in-depth study of natural products such as valerenin of great scientific significance and clinical value. This article aims to provide a systematic review of the chemical properties, plant sources, pharmacological activities, mechanisms of action, pharmacological evaluation, and clinical application prospects of Valerian, in order to provide comprehensive academic references for the in-depth development and utilization of this compound.
Chemical structure and physicochemical properties
Valtrate, chemical name (1S, 4aS, 7aS) -1- [(acetoxy) methyl] -1,4-a, 5,7a-tetrahydro-4a, 7a-dihydroxy-7- (3-methyl-1-oxobutoxy) cyclopentano [c] pyran-4-carboxylic acid methyl ester, CAS number 18296-44-1. Its molecular formula is C22H30O8 and its molecular weight is 422.4740.
Structurally, Valerian belongs to the class of iridoid esters, with its core skeleton being a dihydrocyclopentano [c] pyran ring. Multiple functional groups are attached to this ring, including one acetoxymethyl group, two hydroxyl groups (positions 4a, 7a), one methyl ester group, and a key 3-methylbutyryloxy group (valerolac acid ester). This highly functionalized structure makes its chemical properties relatively unstable, especially under light, heat, or alkaline conditions, where its epoxidation and ester bonds are prone to ring opening, hydrolysis, or rearrangement reactions, generating degradation products such as crotonyl oxy derivatives (such as didrovalate), which pose challenges to its extraction, preservation, and in vivo metabolism.
According to the provided pharmacological parameters, the lipid water partition coefficient (LogP) of Valerian is 2.8120, indicating its moderate lipophilicity, which facilitates its penetration through biological membranes, especially the blood-brain barrier (predicted as high permeability). Its topological polar surface area (TPSA) is 100.6600 Å ², reflecting the polarity brought by multiple oxygen atoms in the molecule. The water solubility value is 0.0869 (usually measured in mg/mL or mol/L, not specified here, but the value is relatively low), indicating that its solubility in water is limited and it belongs to insoluble compounds. These physicochemical properties directly affect their drug absorption, distribution, and formulation development strategies.
Plant sources and extraction methods
Valerian is mainly derived from plants of the genus Valeriana in the family Caprifoliaceae, with the roots and rhizomes of medicinal Valeriana officinalis L. being the main commercial source. In addition, different types of valerian such as V. jatamansi Jones also contain a certain amount of valine and its homologs. Valerian is usually present in plants along with its homologs such as acevalite, didrovalate, etc. Its content is significantly affected by factors such as plant variety, origin, harvest season, growth period, and storage conditions.
Due to the sensitivity of Valerian to thermal and chemical environments, its extraction and separation processes require precise control. Traditional extraction methods often use organic solvent cold soaking or percolation methods, with commonly used solvents including methanol, ethanol, dichloromethane, or mixed solvents of different proportions, to maximize the extraction of target components and reduce degradation. Modern extraction techniques such as ultrasound assisted extraction, microwave-assisted extraction, and supercritical CO2 fluid extraction have been applied to improve extraction efficiency, shorten time, and reduce thermal degradation risk.
The crude extract after extraction needs further separation and purification to obtain high-purity valine. Conventional column chromatography techniques, such as silica gel column chromatography and reverse phase silica gel column chromatography (RP-C18), are commonly used separation methods. High performance liquid chromatography (HPLC), especially preparative HPLC, has become a key tool for separating and purifying valine and its analogues, achieving high resolution and recovery. During the entire extraction and separation process, attention should be paid to avoiding light, operating at low temperatures, and using inert gas protection (such as nitrogen) to prevent oxidative degradation.
Pharmacological activity research
The core pharmacological activity of Valerian is mainly reflected in its regulatory effect on the central nervous system, manifested as significant sedative, hypnotic, and anti anxiety effects.
1. Sedative and hypnotic activity:
Numerous in vivo experiments have confirmed that valine can effectively reduce the autonomous activity of experimental animals, synergize with central inhibitors such as pentobarbital sodium, significantly shorten sleep latency and prolong sleep duration. This behavioral sedative hypnotic effect is similar to classical benzodiazepines, but studies have shown differences in its mechanism of action, suggesting that it may have better safety, such as lower dependence risk.
2. Anti anxiety activity:
In classic anxiety animal model experiments such as elevated cross maze, light dark box, and social interaction, both extract and purified valine have shown clear anti anxiety effects, which can increase the exploration time and activity of animals in open or bright areas without affecting their basic motor coordination ability.
3. Other potential activities:
In addition to its central nervous system effects, some studies suggest that valine may have anticonvulsant, muscle relaxant, and potential anti-tumor activity. For example, in vitro studies have shown that valine exhibits cytotoxicity towards certain cancer cell lines. However, further systematic research is still needed to confirm the strength and mechanism of these activities.
It is worth noting that the pharmacological activity of Valerian may not be the effect of a single component, but rather the result of a "multi-component multi-target" effect network composed of its own and its transformation products (such as degradation products or metabolites) in vitro and in vivo. This also explains why in some studies, the total extract of Valerian is more effective than a single high-purity Valerian extract.
Mechanism of action and molecular targets
The molecular mechanism by which Valerian exerts sedative, hypnotic, and anti anxiety effects is complex, involving the regulation of multiple key targets in the central nervous system neurotransmitter system. Current research mainly focuses on its effects on the gamma aminobutyric acid (GABA) system and the serotonin (5-HT) system.
1. Regulation of GABAergic system:
GABA is the most important inhibitory neurotransmitter in the central nervous system. Valerian does not directly act on the benzodiazepine binding site of the GABA-A receptor, but studies have shown that it and its metabolites may act as positive allosteric modulators of the receptor, enhancing the binding affinity between GABA and the receptor or increasing the frequency of GABA activated chloride ion channel opening, thereby enhancing central inhibitory effects. The relevant targets include various subunits of GABA-A receptors, such as GABRA1 (α 1), GABRB2 (β 2), and GABRG2 (γ 2). This indirect, allosteric regulatory mode may be one of the reasons why its therapeutic efficacy and side effects (such as hangover effects and memory impairment) are lower than traditional benzodiazepines.
2. Serotonin can regulate the system:
The 5-HT system is crucial in regulating emotions and sleep. The action of Valerian involves the reuptake of 5-HT and the regulation of its receptor activity.
* 5-HT reuptake inhibition: Valerian may reduce the reuptake of 5-HT in synaptic cleft by inhibiting the function of 5-hydroxytryptamine transporter (SERT, encoded by SLC6A4 gene), thereby increasing the concentration of 5-HT in synaptic cleft, which partially overlaps with the mechanism of action of many antidepressant/anti anxiety drugs.
* 5-HT receptor regulation: Research suggests that valine may have regulatory effects on specific subtypes of 5-HT receptors. For example, the excitatory effect on 5-HT1A receptor (HTR1A) can produce anti anxiety and sedative effects; The antagonism or downregulation of 5-HT2A receptor (HTR2A) is associated with improving sleep structure (increasing slow wave sleep), anti anxiety, and antipsychotic effects.
3. Multi target synergistic effect:
In summary, Valerian is likely to exert its overall effect of "soothing nerves and promoting sleep" by simultaneously mildly enhancing GABAergic inhibition, inhibiting 5-HT reuptake, and regulating specific 5-HT receptor subtypes (such as activating 5-HT1A and antagonizing 5-HT2A) through multiple pathways. This multi-target mode of action is consistent with the characteristics of natural product action and may also help explain its relatively mild and balanced clinical effects.
Evaluation of drug properties and pharmacokinetics
Based on the provided pharmacological parameters and existing research, a preliminary evaluation of the pharmacological properties of Valerian is conducted
1. Absorption, distribution, metabolism, and excretion (ADME):
* Absorption and distribution: The moderate LogP value (2.8120) and high blood-brain barrier penetration prediction of valine support its ability to be absorbed by the gastrointestinal tract and effectively enter the target sites of the central nervous system after oral administration, which is a key prerequisite for its central activity. However, its low water solubility may limit its dissolution rate in gastrointestinal fluids, thereby affecting oral bioavailability. This suggests that solubilization techniques (such as solid dispersions, cyclodextrin inclusion, nano formulations, etc.) may be needed in formulation development.
* Metabolism and excretion: Valerian is rapidly and complexly metabolized in the body. The liver is its main metabolic site, producing a series of metabolites through esterase hydrolysis, epoxide ring opening, oxidation, and binding reactions (such as glucuronidation). Among them, some degradation products (such as ballinal and homobardrinal) are also considered to have biological activity. Valerian and its metabolites are mainly excreted through the kidneys and bile. Its instability leads to low concentrations and short half lives of the prototype drug in the blood, which poses challenges for pharmacokinetic research.
2. Preliminary safety evaluation:
* HERG inhibition: The data shows that it has no hERG potassium channel inhibitory effect ("no"), which is a positive signal indicating that it may not have a potential risk of causing QT interval prolongation and apical torsion type ventricular tachycardia, and its cardiovascular safety is relatively good.
* Genetic toxicity: The Ames test result is 0.9 (usually expressed as the ratio of the number of revertant mutant colonies to the control, close to 1 indicating negative or weakly positive), which suggests that there is no significant mutagenicity in the bacterial testing system, but a more comprehensive evaluation needs to be conducted in conjunction with mammalian cell assays.
* General toxicity: Traditional Valerian preparations are generally safe for clinical use, but the potential liver toxicity risks associated with high-dose or long-term use of pure compounds have been mentioned in a few studies, which may be related to the activity of their intermediate metabolites and require close attention in drug development.
3. Challenges in drug development:
The main challenges lie in its chemical instability (leading to complex production, storage, and in vivo metabolism), poor water solubility (affecting formulation and absorption), and incomplete systematic pharmacokinetic and toxicological data. Future research needs to focus on the synthesis of stabilized derivatives, the development of novel drug delivery systems, and comprehensive preclinical ADME/Tox studies.
Clinical application prospects and prospects
Valerian and its source plant, Valerian, have a certain foundation in clinical application, mainly used as dietary supplements or traditional herbs to alleviate mild nervous tension, anxiety, and sleep disorders. However, developing high-purity valine into modern innovative drugs still faces opportunities and challenges.
1. Potential clinical application directions:
* Adjuvant treatment for mild to moderate anxiety and insomnia: As a potential alternative or supplement to benzodiazepines and Z-drugs (such as zolpidem), it is particularly suitable for patients who are concerned about dependency and tolerance issues.
* Emotional comfort during the perioperative period or stress state: Utilize its relatively mild sedative properties to help patients alleviate preoperative anxiety or stress reactions.
* Combination therapy with other drugs: Explore the combination of low-dose conventional sedatives and hypnotics to enhance efficacy, reduce dosage and side effects.
2. Future research and development prospects:
* Structural optimization and derivative development: In response to the unstable epoxidation structure and ester bonds of Valerian, structural modifications are carried out through semi synthetic or biosynthetic means to improve its chemical stability, pharmacokinetic properties (such as prolonging half-life), and enhance targeting selectivity, while retaining or enhancing its activity.
* Application of advanced formulation technology: Utilizing novel delivery systems such as nanocrystals, liposomes, and polymer micelles to address their water solubility issues, improve oral bioavailability, and explore the possibility of targeted delivery to the brain.
* Deep analysis of the mechanism of action: By utilizing techniques such as molecular docking, chemical biology probes, and gene knockout/knock in animal models, we aim to more accurately elucidate the specific patterns and structure-activity relationships of its interactions with GABA-A receptor subtypes, 5-HT receptors, and transporters.
* High standard clinical research: Conduct rigorously designed, large sample, randomized double-blind placebo-controlled clinical trials to confirm their effectiveness and safety in treating specific types of anxiety or insomnia, establish clear dose-response relationships, and provide solid evidence for drug registration.
* Quality standardization: Establish a comprehensive quality control standard for Valerian and its key active ingredients from raw material cultivation to final product, ensuring consistency between product batches and reproducibility of therapeutic effects.
Conclusion
As one of the core active ingredients of the traditional medicinal plant Valeriana officinalis, its unique cyclohexene ether terpene ester structure endows it with pharmacological properties of multi-target regulation of GABAergic and 5-HTergic nervous systems, demonstrating clear application potential in sedation, hypnosis, and anti anxiety. Although there are challenges in terms of chemical stability, solubility, and systemic pharmacokinetics, modern research methods in medicinal chemistry, pharmacy, and pharmacology provide the possibility to overcome these bottlenecks. Through in-depth research on its mechanism of action, rational structural modifications, innovative formulation development, and rigorous clinical validation, Valerian is expected to transform from a traditional plant component into a modern natural source drug with clear molecular mechanisms, controllable quality, and precise efficacy, providing a new and potentially safer treatment option to meet the growing global demand for mental health. Continuous and in-depth research on it not only has value in the development of new drugs, but will also further enrich our understanding of the complex functional networks of natural products.
